Sensei Biotherapeutics, Inc. (SNSE)

Sensei Biotherapeutics' stock price has experienced significant upward movement over the past six months. In October 2025, Sensei Biotherapeutics announced a strategic review, discontinuing the development of solnerstotug and exploring strategic alternatives. In February 2026, the company announced the acquisition of Faeth Therapeutics and a concurrent $200 million private placement. In March 2026, Sensei Biotherapeutics reported its full-year 2025 financial results, following the acquisition of Faeth Therapeutics and the private placement.

As a clinical-stage biotechnology company focused on developing therapeutics for cancer, the demand for Sensei Biotherapeutics' products and services is not subject to typical seasonal fluctuations. Demand is primarily driven by factors such as the prevalence of the diseases it aims to treat, the success of its clinical trials, regulatory approvals, and market adoption of its therapies, rather than seasonal patterns.

Sensei Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing next-generation therapeutics for cancer patients, operating within the Healthcare sector, specifically in Biotechnology and Drug Discovery. The company utilizes its Tumor Microenvironment Activated Biologics (TMAb™) platform to develop selective therapeutics designed to either disable immunosuppressive signals or activate immunostimulatory signals specifically within the tumor microenvironment. Its former lead product candidate was solnerstotug, which was in Phase 1/2 clinical trials for solid tumors. Following the acquisition of Faeth Therapeutics, PIKTOR became Sensei's new lead program, with ongoing Phase 2 and planned Phase 1b trials for advanced endometrial and HR+/HER2- advanced breast cancer, respectively.

Sensei Biotherapeutics, Inc. is headquartered in Rockville, Maryland, United States, and maintains a location in Boston, Massachusetts, United States.

Sensei Biotherapeutics' brand reputation has been shaped by its clinical development progress and strategic corporate decisions. The company regularly participates in scientific and investor conferences. The company discontinued the development of solnerstotug, and explore strategic alternatives, followed by a strategic pivot with the acquisition of Faeth Therapeutics and a substantial private placement, which introduced a new lead program, PIKTOR. The company's focus on immuno-oncology and its TMAb™ platform are central to its scientific identity.

Sensei Biotherapeutics, Inc. has a mix of institutional and insider ownership. As of March 2026, institutional investors hold 3.83% to 10.50% of the stock. James Peyer is noted as the largest individual shareholder, owning 5.34 million shares, representing 423.65% of the company.